Alex Lee Zhu

Alex Lee Zhu

Auto-generated profile, based on publicly available information

Alex Lee Zhu

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KMKatherine McMahan
Katherine McMahan
JYJingyou Yu
Jingyou Yu
NMNoe Bladimir Mercado
Noe Bladimir Mercado
CLCarolin Loos
Carolin Loos
LTLisa H. Tostanoski
Lisa H. Tostanoski
DBDan H. Barouch
Dan H. Barouch

1 October 2020 in Cell
Verified
Journal Article
Closed access
NKNaoki Kaneko
Naoki Kaneko
HKHsiao-Hsuan Kuo
Hsiao-Hsuan Kuo
JBJulie Boucau
Julie Boucau
JFJocelyn R. Farmer
Jocelyn R. Farmer
HAHugues Allard-Chamard
Hugues Allard-Chamard
SPShiv Pillai
Shiv Pillai

19 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
PAPrabhu S. Arunachalam
Prabhu S. Arunachalam
AWAlexandra C. Walls
Alexandra C. Walls
NGNadia Golden
Nadia Golden
CACaroline Atyeo
Caroline Atyeo
SFStephanie Fischinger
Stephanie Fischinger
BPBali Pulendran
Bali Pulendran

31 August 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
MGMatthew J. Gorman
Matthew J. Gorman
NPNita Patel
Nita Patel
MGMimi Guebre-Xabier
Mimi Guebre-Xabier
AZAlex L. Zhu
Alex L. Zhu
CACaroline Atyeo
Caroline Atyeo
GAGalit Alter
Galit Alter
Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 variants. Collectively, the data presented here suggest that a single dose may prevent disease via combined Fc/Fab functions but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.

15 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YBYannic C Bartsch
Yannic C Bartsch
SFStephanie Fischinger
Stephanie Fischinger
SSSameed M Siddiqui
Sameed M Siddiqui
ZCZhilin Chen
Zhilin Chen
JYJingyou Yu
Jingyou Yu
GAGalit Alter
Galit Alter
Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only serve as a surrogate of protection. Instead, the ability of vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked to protection. While evidence has begun to point to persisting antibody responses among SARS-CoV-2 infected individuals, cases of re-infection have begun to emerge, calling the protective nature of humoral immunity against this highly infectious pathogen into question. Using a community-based surveillance study, we aimed to define the relationship between titers and functional antibody activity to SARS-CoV-2 over time. Here we report significant heterogeneity, but limited decay, across antibody titers amongst 120 identified seroconverters, most of whom had asymptomatic infection. Notably, neutralization, Fc-function, and SARS-CoV-2 specific T cell responses were only observed in subjects that elicited RBD-specific antibody titers above a threshold. The findings point to a switch-like relationship between observed antibody titer and function, where a distinct threshold of activity—defined by the level of antibodies—is required to elicit vigorous humoral and cellular response. This response activity level may be essential for durable protection, potentially explaining why re-infections occur with SARS-CoV-2 and other common coronaviruses.

27 July 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
JFJoseph Francica
Joseph Francica
BFBarbara J. Flynn
Barbara J. Flynn
KFKathryn E. Foulds
Kathryn E. Foulds
ANAmy T. Noe
Amy T. Noe
AWAnne P. Werner
Anne P. Werner
RSRobert Seder
Robert Seder
Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike protein trimers (preS dTM) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were formulated with the adjuvant AS03 and administered twice to nonhuman primates (NHP). Binding and functional neutralization assays and systems serology revealed that the vaccinated NHP developed AS03-dependent multi-functional humoral responses that targeted distinct domains of the spike protein and bound to a variety of FC receptors mediating immune cell effector functions in vitro. The neutralizing 50% inhibitory concentration (IC50) titers for pseudovirus and live SARS-CoV-2 were higher than titers for a panel of human convalescent serum samples. NHP were challenged intranasally and intratracheally with a high dose (3x106 plaque forming units, PFU) of SARS-CoV-2 (USA-WA1/2020 isolate). Two days post-challenge, vaccinated NHP showed rapid control of viral replication in both the upper and lower airways. Notably, vaccinated NHP also had increased spike protein-specific IgG antibody responses in the lung as early as two days post challenge. Moreover, passive transfer of vaccine-induced IgG to hamsters mediated protection from subsequent SARS-CoV-2 challenge. These data show that antibodies induced by the AS03-adjuvanted preS dTM vaccine were sufficient to mediate protection against SARS-CoV-2 in NHP and that rapid anamnestic antibody responses in the lung may be a key mechanism for protection.